Structure Therapeutics Inc. (GPCR) Stock
GPCR has an Alpha Score of 17 out of 100 (poor), computed on Nov 10, 2026 from 2 of 4 sub-scores. 1 member of Congress disclosed 1 trade in GPCR since 2023: 0 purchases and 1 sale, most recently Thomas R Carper (sale, Oct 4, 2023). 3 of the hedge funds AlphaScala tracks reported GPCR in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Marshall Wace's at $14.36M.
What is GPCR's Alpha Score?
How it works →Alpha Score of 17 reflects poor overall profile with poor momentum, moderate quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 10, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Structure Therapeutics Inc. (GPCR)?
Most recent: Thomas R Carper (sale, Oct 4, 2023); records start Oct 4, 2023.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Tom Carper D-DE · Senate | 2023-10-04 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 9, 2026.
See all GPCR political trades →Which hedge funds own GPCR?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Marshall Wace | 268K | $14.36M | +287% |
| D.E. Shaw David Shaw | 115K | $6.19M | -44% |
| Millennium Management Israel Englander | 90K | $4.81M | -47% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →What are GPCR's key statistics?
Key statistics as of Nov 10, 2026
GPCR price chart
Powered by TradingViewWhat does Structure Therapeutics Inc. do?
Structure Therapeutics Inc. is a biopharmaceutical company engaged in the discovery and development of innovative therapies aimed at treating serious human diseases. The primary focus of Structure Therapeutics Inc. is on the structural biology-based approach to discover novel small molecule drugs, particularly in the field of G protein-coupled receptors (GPCRs). These receptors are critical elements in various physiological processes, making them significant drug targets for numerous challenging ailments, including metabolic, cardiovascular, and neurological disorders. The company's unique approach involves leveraging cutting-edge technologies to decipher the complex structures of GPCRs, which aids in the design of more effective and efficient therapeutic solutions. By harnessing the power of structural biology, Structure Therapeutics Inc. aims to address unmet medical needs, potentially transforming treatment protocols in key healthcare sectors. As an emerging entity in the pharmaceutical landscape, it plays a crucial role in advancing drug discovery methodologies and fostering collaboration across scientific and medical communities to improve patient outcomes.